News
LBTSF
15.35
NaN%
--
Almirall Calls 2026 Shareholders’ Meeting with Governance Changes and Scrip Dividend Plan
TipRanks · 04/08 17:37
Lilly says once-monthly eczema injectable delivered durable disease control
Seeking Alpha · 03/27 15:02
Almirall presents long-term interim results from Phase 3b ADlong study
TipRanks · 03/27 13:05
Almirall presents clinical, real-word data across portfolio at AAD meeting
TipRanks · 03/26 11:15
Almirall Updates Board Regulations to Strengthen Corporate Governance Framework
TipRanks · 03/19 14:24
Almirall downgraded to Hold from Buy at Deutsche Bank
TipRanks · 03/02 10:30
Kepler Capital Sticks to Their Buy Rating for Almirall (0O9B)
TipRanks · 02/25 01:38
Almirall Schedules Webcast to Present 2025 Financial Results
TipRanks · 02/24 12:04
Almirall Publishes 2025 Corporate Governance Report in Enhanced Narrative Format
TipRanks · 02/24 12:04
Almirall’s 2025 Pay Report Highlights Strong Dermatology Growth and Governance Backing
TipRanks · 02/24 12:03
Almirall Posts Slight Decline in Total Assets as 2025 Balance Sheet Remains Stable
TipRanks · 02/24 12:03
Almirall Issues FY 2025 Update With Strictly Informational Disclaimer
TipRanks · 02/24 12:02
Almirall, S.A. reports FY 2025 results
Seeking Alpha · 02/23 10:57
Almirall FY25 Results Climb, Sees Growth In FY26
NASDAQ · 02/23 10:21
Almirall downgraded to Neutral from Outperform at BNP Paribas
TipRanks · 01/20 10:30
Almirall, S.A. reports 9M results
Seeking Alpha · 11/10/2025 20:54
Weekly Report: what happened at LBTSF last week (0908-0912)?
Weekly Report · 09/15/2025 10:46
Weekly Report: what happened at LBTSF last week (0901-0905)?
Weekly Report · 09/08/2025 10:48
Weekly Report: what happened at LBTSF last week (0825-0829)?
Weekly Report · 09/01/2025 10:44
Weekly Report: what happened at LBTSF last week (0818-0822)?
Weekly Report · 08/25/2025 10:52
More
Webull provides a variety of real-time LBTSF stock news. You can receive the latest news about Almirall through multiple platforms. This information may help you make smarter investment decisions.
About LBTSF
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.